Literature DB >> 6957978

The effect of different doses of pirenzepine on gastric secretion stimulated by modified shamfeeding in man.

R W Stockbrügger, B H Jaup, G Dotevall.   

Abstract

It is known, that Pirenzepine inhibits basal, pentagastrin-, insulin- and peptone-stimulated gastric secretion. In this study the effect of three different doses of Pirenzepine was studied on acid secretion stimulated by modified shamfeeding (MSF). Each of eleven healthy volunteers underwent four secretion tests after pre-treatment for 4 days in random order by: no drug, tablets Pirenzepine 25 mg b.i.d., 50 mg b.i.d., or 50 mg t.d.s. Basal acid output 0-30' was reduced by 48%, 59% and 66% respectively and stimulated acid output 0-120' by 45%, 58% and 48% respectively. When acid secretion was calculated as volume corrected for duodeno-gastric reflux and pyloric losses the corresponding figures were 33.7%, 36.3% and 42.6%. Inhibition of MSF-stimulated acid secretion by a high dose of Pirenzepine was not complete. Pirenzepine 50 mg b.i.d. seems to be a suitable dose for clinical use, as acid reduction is as good as with 50 mg t.d.s. and side-effects are known to be less.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6957978

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  3 in total

1.  Identification of muscarinic receptor subtype mediating colonic response to eating.

Authors:  F Narducci; G Bassotti; S Daniotti; P Del Soldato; M A Pelli; A Morelli
Journal:  Dig Dis Sci       Date:  1985-02       Impact factor: 3.199

2.  Treatment of duodenal ulcer with pirenzepine and cimetidine.

Authors:  H Brunner; H Dittrich; P Kratochvil; G Brandstätter; E Hentschel; K Schütze; K H Tragl; H Kern; K Löffelmann; H Zeiler
Journal:  Gut       Date:  1984-02       Impact factor: 23.059

Review 3.  Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases.

Authors:  A A Carmine; R N Brogden
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.